

## Special Issue

# Vaccine Development and Immune Responses in Tuberculosis

### Message from the Guest Editors

Interest in the development of an effective TB has experienced an extraordinary growth in the last 20 years. Despite the numerous proposals that have emerged through these efforts, however, we have sadly seen limited success. Indeed, though several pivotal efficacy trials have begun, leading to a few victories, it appears that this field is in dire need of new approaches, a so-called “pink swan”—a term coined in the field five years ago—in order to find a definitive champion which is able to substitute the old BCG. This means that the design of new strategies should be able to integrate the newest knowledge in the natural history of *Mycobacterium tuberculosis* infection and the latest vaccine design approaches in fields beyond infectious diseases. This is why we invite authors to submit proposals with “out of the box” strategies.

### Guest Editors

Prof. Dr. Pere-Joan Cardona

Microbiology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Catalonia, Spain

Prof. Dr. Petros C. Karakousis

Johns Hopkins School of Medicine, Baltimore, MD, USA

Dr. Rasmus S. Mortensen

Department of Infectious Immunology / TB Vaccine, Statens Serum Institut, 2300 Copenhagen, Denmark

### Deadline for manuscript submissions

closed (31 August 2021)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/66863](https://mdpi.com/si/66863)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).